Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
Open Access
- 4 December 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Sarcoma Research
- Vol. 4 (1), 1-6
- https://doi.org/10.1186/2045-3329-4-17
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2012
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBritish Journal of Cancer, 2012
- Adjuvant treatment of GIST: patient selection and treatment strategiesNature Reviews Clinical Oncology, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal Of Cancer, 2011
- Gastrointestinal stromal tumours: origin and molecular oncologyNature Reviews Cancer, 2011
- Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment optionsJournal of Surgical Oncology, 2011
- Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutationsProceedings of the National Academy of Sciences of the United States of America, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998